Impact Of Cytoterm On Vasomotor Symptoms (VMS) And Quality Of Life (Qol) Impairments In Patients Receiving Hormone Therapy (HT) And Radiotherapy (RT) For Prostate Cancer (Pca). Results Of The ESCULAPE Phase II Study.

被引：0
|
作者：
Belkacemi, Y. [1 ,2 ,3 ]
Jouhaud, A. [2 ,4 ]
Ingels, A. [5 ]
Brunel, A. [6 ]
Coraggio, G. [2 ]
Joly, C. [7 ]
Hadhri, A. [10 ]
Hassani, W. [2 ]
Nourieh, M. [8 ]
Salazar, B. Vega [9 ]
de la Taille, A. [10 ]
Salomon, L. [11 ]
机构：
[1] AROME Assoc Radiotherapy & Oncol Mediterranean Ar, Paris, France
[2] Henri Mondor Univ Hosp, AP HP, Dept Radiat Oncol, Creteil, France
[3] Univ Paris Est Creteil UPEC, Henri Mondor Breast Canc Ctr, INSERM, U955, Creteil, France
[4] Henri Mondor Univ Hosp, AP HP, Henri Mondor Breast Ctr, Creteil, France
[5] Henri Mondor Univ Hosp, Dept Urol, Creteil, France
[6] Stateo, Monaco, Monaco
[7] Henri Mondor Univ Hosp, Dept Med Oncol, Creteil, France
[8] Henri Mondor Univ Hosp, Dept Pathol, Creteil, France
[9] SAM Serelys Pharma, Monaco, Monaco
[10] Univ Paris Est UPEC, Henri Mondor Univ Hosp, AP HP, Dept Urol, Creteil, France
[11] Henri Mondor Hosp, Paris, France
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2020年 / 108卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4014
引用
收藏
页码：E864 / E865
页数：2
相关论文
共 12 条
  • [1] Effect of Serelys Homme on the Incidence and Severity of Vasomotor Symptoms and Quality-of-Life Impairments in Patients Receiving Hormone Therapy and Radiation for Localized Prostate Cancer: Results of the ESCULAPE Phase 2 Prospective Study
    Belkacemi, Yazid
    Coraggio, Gabriele
    Brunel, Anne
    Jouhaud, Annie
    Ingels, Alexandre
    Joly, Charlotte
    Hadhri, Asma
    Hassani, Wissal
    Loganadane, Gokoulakrichenane
    Saldana, Carolina
    Ouidir, Nabila
    Vega, Barbara
    Debbi, Kamel
    de La Taille, Alexandre
    [J]. ADVANCES IN RADIATION ONCOLOGY, 2023, 8 (05)
  • [2] Impact of docetaxel (D)-based chemotherapy on quality of life (QOL) of patients (PTS) with hormone-refractory prostate cancer (HRPC):: Results from a randomised phase II trial with D±estramustine (E)
    Caffo, O.
    Sava, T.
    Comploj, E.
    Zustovich, Z.
    Segati, R.
    Fariello, A.
    Perin, A.
    Sacco, C.
    Caldara, A.
    Galligioni, E.
    [J]. EUROPEAN UROLOGY SUPPLEMENTS, 2008, 7 (03) : 231 - 231
  • [3] Urethral Sparing Intensity Modulated Radiation Therapy (US-IMRT) Is Not Shown To Improve Urinary Quality of Life (QOL) in Low Risk Prostate Cancer (PCa): Results of a Randomized Phase II Trial
    Vainshtein, J. M.
    Abu-Isa, E.
    Olson, K.
    Ray, M. E.
    Sandler, H. M.
    Normolle, D.
    Pan, C.
    Hamstra, D. A.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S414 - S415
  • [4] Quality of life of prostate cancer (PCa) patients with testosterone deficiency symptoms (TDS) before initiation of gonadotropin-releasing hormone (GnRH) agonist therapy: Subgroup analysis of EQUINOXE study
    Droupy, Stephane
    Colson, Marie-Helene
    Ringuet, Nathalie Pello Leprince
    Perrot, Valerie
    Descazeaud, Aurelien
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [5] QUALITY OF LIFE OF PROSTATE CANCER (PCA) PATIENTS WITH TESTOSTERONE DEFICIENCY SYMPTOMS (TDS) BEFORE INITIATION OF GONADOTROPIN-RELEASING HORMONE (GNRH) AGONIST THERAPY, SUBGROUP ANALYSIS OF EQUINOXE STUDY
    Droupy, Stephane
    Colson, Marie-Helene
    Leprince-Ringuet, Nathalie Pello
    Perrot, Valerie
    Descazeaud, Aurelien
    [J]. JOURNAL OF UROLOGY, 2020, 203 : E248 - E248
  • [6] Effect of addition of docetaxel (D) to hormonal therapy (HT) versus HT alone on quality of life: Results from a phase III study in non-metastatic high-risk prostate cancer (PC) patients (pts) with a rising PSA status.
    Oudard, Stephane
    Gillaizeau, Florence
    Peyrard, Severine
    Latorzeff, Igor
    Beuzeboc, Philippe
    Sevin, Emmanuel
    Rolland, Frederic
    Mourey, Loic
    Priou, Franck
    Culine, Stephane
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [7] Quality of life of prostate cancer (PCa) patients aged 60 years and older: Changes in QLQ-ELD14 dimensions after a six-month gonadotropin-releasing hormone agonist (GnRHa) therapy, according to age groups-Primary analysis of PRISME study.
    Rozet, Francois
    Hennequin, Christophe
    Mongiat-Artus, Pierre
    Ringuet, Leprince Nathalie Pello
    Grandoulier, Anne-Sophie
    Roupret, Morgan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [8] Impact of OPTIMOX-aflibercept as first-line therapy on time to health-related quality of life deterioration in patients with unresectable metastatic colorectal cancer: results of the GERCOR VELVET phase II single arm study
    Henriques, Julie
    Anota, Amelie
    Chibaudel, Benoist
    Bachet, Jean Baptiste
    Andre, Thierry
    Auby, Dominique
    Desrame, Jerome
    Hamed, Nabil Baba
    Lecaille, Cedric
    Louvet, Christophe
    Tournigand, Christophe
    Lebrun-Ly, Valerie
    Dauba, Jerome
    Garcia, Marie-Line
    Dubreuil, Olivier
    Attia, Malika
    De Gramont, Aimery
    Bonnetain, Franck
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [9] ADJUVANT CHEMO-HORMONO-THERAPY AFTER RADICAL PROSTATECTOMUY FOR LOCALLY ADVANCED PROSTATE CANCER PATIENTS DOES NOT DELAY CONTINENCE RECOVERY AND HAS A LOW IMPACT ON QUALITY OF LIFE: RESULTS OF MORBIDITY EVALUATION IN PRO 05 PHASE II RANDOMIZED TRIAL
    Ploussard, Guillaume
    Salomon, Laurent
    Paule, Bernard
    Allory, Yves
    Vordos, Dimitri
    Hoznek, Andras
    Abbou, Claude C.
    Culine, Stephane
    de la Taille, Alexandre
    [J]. JOURNAL OF UROLOGY, 2009, 181 (04): : 293 - 293
  • [10] USING ADJUVANT CHEMO-HORMONO-THERAPY AFTER RADICAL PROSTATECTOMUY FOR LOCALLY ADVANCED PROSTATE CANCER PATIENTS DOES NOT DELAY CONTINENCE RECOVERY AND HAS A LOW IMPACT ON QUALITY OF LIFE: RESULTS OF MORBIDITY EVALUATION IN PRO 05 PHASE II RANDOMIZED TRIAL
    Ploussard, G.
    Salomon, L.
    Paule, B.
    Allory, Y.
    Vordos, D.
    Hoznek, A.
    Abbou, C. C.
    Culine, S.
    De La Taille, A.
    [J]. EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (04) : 251 - 251
12